Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice

Fei Ting Hsu, Tzu Chun Chen, Hui Yen Chuang, Ya Fang Chang, Jeng Jong Hwang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Ex vivo expansion of CD8+ T-cells has been a hindrance for the success of adoptive T cell transfer in clinic. Currently, preconditioning with chemotherapy is used to modulate the patient immunity before ACT, however, the tumor microenvironment beneficial for transferring T cells may also be damaged. Here preconditioning with single low dose of doxorubicin or paclitaxel combined with fewer CD8+ T-cells was investigated to verify whether the same therapeutic efficacy of ACT could be achieved. An E.G7/OT1 animal model that involved adoptive transfer of OVA-specific CD8+ T-cells transduced with a granzyme B promoter-driven firefly luciferase and tomato fluorescent fusion reporter gene was used to evaluate this strategy. The result showed that CD8+ T-cells were activated and sustained longer in mice pretreated with one low-dose Dox or Tax. Enhanced therapeutic efficacy was found in Dox or Tax combined with 2×106 CD8+ T-cells and achieved the same level of tumor growth inhibition as that of 5×106 CD8+ T-cells group. Notably, reduced numbers of Tregs and myeloid derived suppressor cells were shown in combination groups. By contrast, the number of tumor-infiltrating cytotoxic T lymphocytes and IL-12 were increased. The NF-kB activity and immunosuppressive factors such as TGF-β, IDO, CCL2, VEGF, CCL22, COX-2 and IL-10 were suppressed. This study demonstrates that preconditioning with single low dose Dox or Tax and combined with two fifth of the original CD8+ T-cells could improve the tumor microenvironment via suppression of NF-kB and its related immunosuppressors, and activate more CD8+ T-cells which also stay longer.

Original languageEnglish
Pages (from-to)44134-44150
Number of pages17
JournalOncotarget
Volume6
Issue number42
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Adoptive Transfer
Paclitaxel
Doxorubicin
T-Lymphocytes
Tumor Microenvironment
NF-kappa B
Firefly Luciferases
Granzymes
Cytotoxic T-Lymphocytes
Lycopersicon esculentum
Interleukin-12
Immunosuppressive Agents
Reporter Genes
Interleukin-10
Vascular Endothelial Growth Factor A
Immunity
Neoplasms
Animal Models
Drug Therapy

Keywords

  • Adoptive T cell transfer
  • Bioluminescent imaging
  • Doxorubicin
  • Immune response
  • Immunity
  • Immunology and microbiology section
  • Immunomodulation
  • NF-kB
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology

Cite this

Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. / Hsu, Fei Ting; Chen, Tzu Chun; Chuang, Hui Yen; Chang, Ya Fang; Hwang, Jeng Jong.

In: Oncotarget, Vol. 6, No. 42, 2015, p. 44134-44150.

Research output: Contribution to journalArticle

Hsu, Fei Ting ; Chen, Tzu Chun ; Chuang, Hui Yen ; Chang, Ya Fang ; Hwang, Jeng Jong. / Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. In: Oncotarget. 2015 ; Vol. 6, No. 42. pp. 44134-44150.
@article{b3cad06fe3134d03a52db8060c5ecade,
title = "Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice",
abstract = "Ex vivo expansion of CD8+ T-cells has been a hindrance for the success of adoptive T cell transfer in clinic. Currently, preconditioning with chemotherapy is used to modulate the patient immunity before ACT, however, the tumor microenvironment beneficial for transferring T cells may also be damaged. Here preconditioning with single low dose of doxorubicin or paclitaxel combined with fewer CD8+ T-cells was investigated to verify whether the same therapeutic efficacy of ACT could be achieved. An E.G7/OT1 animal model that involved adoptive transfer of OVA-specific CD8+ T-cells transduced with a granzyme B promoter-driven firefly luciferase and tomato fluorescent fusion reporter gene was used to evaluate this strategy. The result showed that CD8+ T-cells were activated and sustained longer in mice pretreated with one low-dose Dox or Tax. Enhanced therapeutic efficacy was found in Dox or Tax combined with 2×106 CD8+ T-cells and achieved the same level of tumor growth inhibition as that of 5×106 CD8+ T-cells group. Notably, reduced numbers of Tregs and myeloid derived suppressor cells were shown in combination groups. By contrast, the number of tumor-infiltrating cytotoxic T lymphocytes and IL-12 were increased. The NF-kB activity and immunosuppressive factors such as TGF-β, IDO, CCL2, VEGF, CCL22, COX-2 and IL-10 were suppressed. This study demonstrates that preconditioning with single low dose Dox or Tax and combined with two fifth of the original CD8+ T-cells could improve the tumor microenvironment via suppression of NF-kB and its related immunosuppressors, and activate more CD8+ T-cells which also stay longer.",
keywords = "Adoptive T cell transfer, Bioluminescent imaging, Doxorubicin, Immune response, Immunity, Immunology and microbiology section, Immunomodulation, NF-kB, Paclitaxel",
author = "Hsu, {Fei Ting} and Chen, {Tzu Chun} and Chuang, {Hui Yen} and Chang, {Ya Fang} and Hwang, {Jeng Jong}",
year = "2015",
doi = "10.18632/oncotarget.6628",
language = "English",
volume = "6",
pages = "44134--44150",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "42",

}

TY - JOUR

T1 - Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice

AU - Hsu, Fei Ting

AU - Chen, Tzu Chun

AU - Chuang, Hui Yen

AU - Chang, Ya Fang

AU - Hwang, Jeng Jong

PY - 2015

Y1 - 2015

N2 - Ex vivo expansion of CD8+ T-cells has been a hindrance for the success of adoptive T cell transfer in clinic. Currently, preconditioning with chemotherapy is used to modulate the patient immunity before ACT, however, the tumor microenvironment beneficial for transferring T cells may also be damaged. Here preconditioning with single low dose of doxorubicin or paclitaxel combined with fewer CD8+ T-cells was investigated to verify whether the same therapeutic efficacy of ACT could be achieved. An E.G7/OT1 animal model that involved adoptive transfer of OVA-specific CD8+ T-cells transduced with a granzyme B promoter-driven firefly luciferase and tomato fluorescent fusion reporter gene was used to evaluate this strategy. The result showed that CD8+ T-cells were activated and sustained longer in mice pretreated with one low-dose Dox or Tax. Enhanced therapeutic efficacy was found in Dox or Tax combined with 2×106 CD8+ T-cells and achieved the same level of tumor growth inhibition as that of 5×106 CD8+ T-cells group. Notably, reduced numbers of Tregs and myeloid derived suppressor cells were shown in combination groups. By contrast, the number of tumor-infiltrating cytotoxic T lymphocytes and IL-12 were increased. The NF-kB activity and immunosuppressive factors such as TGF-β, IDO, CCL2, VEGF, CCL22, COX-2 and IL-10 were suppressed. This study demonstrates that preconditioning with single low dose Dox or Tax and combined with two fifth of the original CD8+ T-cells could improve the tumor microenvironment via suppression of NF-kB and its related immunosuppressors, and activate more CD8+ T-cells which also stay longer.

AB - Ex vivo expansion of CD8+ T-cells has been a hindrance for the success of adoptive T cell transfer in clinic. Currently, preconditioning with chemotherapy is used to modulate the patient immunity before ACT, however, the tumor microenvironment beneficial for transferring T cells may also be damaged. Here preconditioning with single low dose of doxorubicin or paclitaxel combined with fewer CD8+ T-cells was investigated to verify whether the same therapeutic efficacy of ACT could be achieved. An E.G7/OT1 animal model that involved adoptive transfer of OVA-specific CD8+ T-cells transduced with a granzyme B promoter-driven firefly luciferase and tomato fluorescent fusion reporter gene was used to evaluate this strategy. The result showed that CD8+ T-cells were activated and sustained longer in mice pretreated with one low-dose Dox or Tax. Enhanced therapeutic efficacy was found in Dox or Tax combined with 2×106 CD8+ T-cells and achieved the same level of tumor growth inhibition as that of 5×106 CD8+ T-cells group. Notably, reduced numbers of Tregs and myeloid derived suppressor cells were shown in combination groups. By contrast, the number of tumor-infiltrating cytotoxic T lymphocytes and IL-12 were increased. The NF-kB activity and immunosuppressive factors such as TGF-β, IDO, CCL2, VEGF, CCL22, COX-2 and IL-10 were suppressed. This study demonstrates that preconditioning with single low dose Dox or Tax and combined with two fifth of the original CD8+ T-cells could improve the tumor microenvironment via suppression of NF-kB and its related immunosuppressors, and activate more CD8+ T-cells which also stay longer.

KW - Adoptive T cell transfer

KW - Bioluminescent imaging

KW - Doxorubicin

KW - Immune response

KW - Immunity

KW - Immunology and microbiology section

KW - Immunomodulation

KW - NF-kB

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84953432232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953432232&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6628

DO - 10.18632/oncotarget.6628

M3 - Article

VL - 6

SP - 44134

EP - 44150

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 42

ER -